Inhibikase Therapeutics (IKT)
Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.
$2.33
vs last close+0.13 (+5.79%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 84.66% | 118.13M shares | |
|---|---|---|---|
| 107 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.31% | 3.23M shares | |
| 7 holders · as of Jul 31, 2026 | |||
| Strategic holders | 14.33% | 19.99M shares | |
| 2 holders · as of Jul 31, 2026 | |||
| Adds to | 101.30% | ||
139.54M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.30%; nothing is left for Other.
13F, as of Jun 30, 2026
107 holders · 118.13M shares · 20 new positions · 68 increased · 23 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Sands Capital Ventures, LLC | 13.02M | 9.33% | 0 | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 10.88M | 7.79% | 0 | Aug 11, 2026 |
| Trails Edge Capital Partners, LP | 9.05M | 6.49% | +994.0K | Aug 14, 2026 |
| Fairmount Funds Management LLC | 8.63M | 6.18% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 7.77M | 5.57% | +1.46M | Aug 7, 2026 |
| Adar1 Capital Management, LLC | 7.39M | 5.29% | +780.6K | Aug 14, 2026 |
| Blackstone Inc. | 5.94M | 4.26% | 0 | Aug 14, 2026 |
| Siren, L.L.C. | 5.85M | 4.19% | 0 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sands Capital Ventures, LLCincl. Frank M. Sands, Sands Capital Life Sciences Pulse Fund II, L.P. | 16.30% | 10.95M | 13G | Oct 25, 2024 |
| RA Capital Management, L.P. | 15.90% | 25.00M | 13G | Jul 17, 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10.80% | 13.02M | 13G | Feb 13, 2026 |
| Steven Boydincl. Armistice Capital, LLC | 9.99% | Nov 14, 2024 | ||
| Soleus Private Equity Fund III, L.P.incl. Soleus Capital Master Fund, L.P., Soleus Capital Group, LLC +5 more | 9.99% | 7.23M | 13G | Oct 28, 2024 |
| Perceptive Life Sciences Master Fund, Ltd.incl. Perceptive Advisors LLC, Joseph Edelman | 9.99% | 6.80M | 13G | Oct 22, 2024 |
| Capital Master LPincl. Capital LP | 9.99% | 6.81M | 13G | Oct 17, 2024 |
| ADAR1 Capital Management, LLC | 9.90% | 13.86M | 13G | May 15, 2026 |
| Commodore Capital LP | 9.90% | 14.05M | 13G | May 15, 2026 |
| Fairmount Funds Management LLC | 9.90% | 12.46M | 13G | Feb 17, 2026 |
| Peter Harwinincl. Tomas Kiselak, Fairmount Healthcare Fund II L.P. +1 more | 9.90% | 6.62M | 13G | Oct 17, 2024 |
| Perceptive Advisors LLC | 8.90% | 12.64M | 13G | May 15, 2026 |
| LLCincl. Holdings LLC | 8.69% | 5.84M | 13G | Oct 28, 2024 |
| Point72 Capital Advisors, Inc.incl. Steven A. Cohen, Point72 Asset Management, L.P. | 8.40% | 13G | Oct 10, 2024 | |
| Trails Edge Capital Partners, LP | 6.10% | 8.06M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P.10 percent owner | Purchase | 2,068,965 | $1.45 | 13,018,965 |
House and Senate disclosures
Not reported.